Sumatriptan intranasal - Dr Reddys Laboratories

Drug Profile

Sumatriptan intranasal - Dr Reddys Laboratories

Alternative Names: DFN-02; DFP 02

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator Dr Reddys Laboratories
  • Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 07 Jun 2017 Updated adverse events and efficacy data from a phase II trial in migraine released by Promius Pharma
  • 04 Apr 2017 Phase-III development for Migraine is ongoing in USA
  • 11 Jul 2016 Dr Reddy's Laboratories initiates a phase II trial in Migraine in USA (NCT02856802)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top